A Single-center, Randomized, Open-label, Two-arm Study to Evaluate the Ovarian Function Inhibition of a Monophasic Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and a Monophasic COC Containing 20mcg Ethinylestradiol (EE)/3 mg DRSP (YAZ), Administered Orally Once Daily in a 24/4 Day Regimen for Three Consecutive Cycles

Trial Profile

A Single-center, Randomized, Open-label, Two-arm Study to Evaluate the Ovarian Function Inhibition of a Monophasic Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and a Monophasic COC Containing 20mcg Ethinylestradiol (EE)/3 mg DRSP (YAZ), Administered Orally Once Daily in a 24/4 Day Regimen for Three Consecutive Cycles

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Estelledrospirenone/estetrol (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Estetra S.A.
  • Most Recent Events

    • 22 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 28 Mar 2018 Planned End Date changed from 31 Mar 2018 to 8 Jun 2018.
    • 28 Mar 2018 Planned primary completion date changed from 31 Jan 2018 to 8 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top